

**Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17] (European Urology (2023) 83(4) (313–317), (S0302283822025386), (10.1016/j.eururo.2022.07.023))**

Gil-Jimenez, Alberto; van Dorp, Jeroen; Contreras-Sanz, Alberto; van der Vos, Kristan; Vis, Daniel J.; Braaf, Linde; Broeks, Annegien; Alcaraz, Antonio; Wessels, Lodewyk F.A.; More Authors

**DOI**

[10.1016/j.eururo.2023.03.002](https://doi.org/10.1016/j.eururo.2023.03.002)

**Publication date**

2023

**Document Version**

Final published version

**Published in**

European Urology

**Citation (APA)**

Gil-Jimenez, A., van Dorp, J., Contreras-Sanz, A., van der Vos, K., Vis, D. J., Braaf, L., Broeks, A., Alcaraz, A., Wessels, L. F. A., & More Authors (2023). Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17] (European Urology (2023) 83(4) (313–317), (S0302283822025386), (10.1016/j.eururo.2022.07.023)). *European Urology*, 83(6), e165.  
<https://doi.org/10.1016/j.eururo.2023.03.002>

**Important note**

To cite this publication, please use the final published version (if applicable).  
Please check the document version above.

**Copyright**

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

**Takedown policy**

Please contact us and provide details if you believe this document breaches copyrights.  
We will remove access to the work immediately and investigate your claim.

***Green Open Access added to TU Delft Institutional Repository***

***'You share, we take care!' - Taverne project***

**<https://www.openaccess.nl/en/you-share-we-take-care>**

Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



## Corrigendum

# Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17]

Alberto Gil-Jimenez<sup>a,b,1</sup>, Jeroen van Dorp<sup>a,1</sup>, Alberto Contreras-Sanz<sup>c</sup>, Kristan van der Vos<sup>a</sup>, Daniel J. Vis<sup>a,b</sup>, Linde Braaf<sup>d</sup>, Annegien Broeks<sup>d</sup>, Ron Kerkhoven<sup>e</sup>, Kim E.M. van Kessel<sup>f</sup>, María José Ribal<sup>g</sup>, Antonio Alcaraz<sup>g</sup>, Lodewyk F.A. Wessels<sup>a,b,h</sup>, Roland Seiler<sup>i,j</sup>, Jonathan L. Wright<sup>k</sup>, Lourdes Mengual<sup>g</sup>, Joost Boormans<sup>f</sup>, Bas W.G. van Rhijn<sup>l,m</sup>, Peter C. Black<sup>c</sup>, Michiel S. van der Heijden<sup>a,n,\*</sup>

<sup>a</sup>Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands; <sup>b</sup>Oncode Institute, Utrecht, The Netherlands; <sup>c</sup>The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, Canada; <sup>d</sup>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands; <sup>e</sup>Core Facility Genomics, Netherlands Cancer Institute, Amsterdam, The Netherlands; <sup>f</sup>Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; <sup>g</sup>Laboratory and Department of Urology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Universitat de Barcelona, Barcelona, Spain; <sup>h</sup>Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands; <sup>i</sup>Department of BioMedical Research, University of Bern, Bern, Switzerland; <sup>j</sup>Department of Urology, Hospital Center Biel, Biel, Switzerland; <sup>k</sup>Department of Urology, University of Washington School of Medicine, Seattle, WA, USA; <sup>l</sup>Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands; <sup>m</sup>Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; <sup>n</sup>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

The authors regret that the following statement regarding author contributions was missed:

Kristan van der Vos is currently a Scientific Editor for Cell Reports Medicine, which is published by Elsevier. Dr van der Vos was not involved in the peer-review process or editorial discussions about this manuscript.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.eururo.2022.07.023>

<sup>1</sup> These authors contributed equally to this work.

\* Corresponding author. Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands, Tel. +31 20 5120 000.

E-mail address: [ms.vd.heijden@nki.nl](mailto:ms.vd.heijden@nki.nl) (M.S. van der Heijden).

<https://doi.org/10.1016/j.eururo.2023.03.002>

0302-2838/© 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

